News articles about Kala Pharmaceuticals (NASDAQ:KALA) have trended somewhat positive on Thursday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.9987704526845 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of research analysts recently weighed in on the stock. Wedbush reiterated a “buy” rating and issued a $46.00 price objective on shares of Kala Pharmaceuticals in a research note on Thursday, November 30th. BidaskClub upgraded shares of Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 29th. Finally, Wells Fargo reiterated a “buy” rating on shares of Kala Pharmaceuticals in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $35.80.
Shares of Kala Pharmaceuticals stock traded up $0.42 during trading hours on Thursday, reaching $17.38. 7,618 shares of the company’s stock traded hands, compared to its average volume of 390,028. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. Kala Pharmaceuticals has a 1 year low of $11.81 and a 1 year high of $26.75.
TRADEMARK VIOLATION NOTICE: “Kala Pharmaceuticals (KALA) Receives Media Impact Rating of 0.13” was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/03/22/kala-pharmaceuticals-kala-receiving-somewhat-favorable-press-coverage-analysis-shows/1973517.html.
About Kala Pharmaceuticals
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.